IR Notice
26 January 2021
Dear Investors,
This is John Rim, CEO of Samsung Biologics.
First, I want thank you all for your continued interest and support in Samsung Biologics.
Achieved "1 trillion won" in revenue within 9 yearslt would be an understatement to say that our daily lives have changed in 2020 due to hte COVID-19 pandemic. Yet even through the extraordinary global events of last year, Samsung Biologics, I ask for your continued warm attention and support. Sincerely,' sales volume increased for all three plants, and we achieved 1,164.8B KRW in revenue,
John Rim President and CEO, Samsung Biologics
an increase of 463B KRW(66%) from the previous year. And operating profit was reported at KRW292.8 billion, reflecting an operating margin of 25%, a 12%p increase of KRW201.1 billion, doubling our prior year's record attributable to substantial operating leverage. l ma very pleased to share that we kept our promise of "1 trillion won in 2020" as announced during our IPO in 2016.2020 Performance
- 47 CMO Accumulated Contracts
- Ground breaking for Plant 4 with capacity of 256,000L
- Geographical Expansion of CDO Lab
- Proprietary cell line launch 'S-CHOice'
From the onset of the global pandemic, Samsung Biologics maintained stable business operations for our valued clients, providing world-class development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic.
Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2,
John Rim President and CEO, Samsung Biologics
and near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services.2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely,
John Rim President and CEO, Samsung Biologics
As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years:
- Capacity Expansion
- By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion
- Geography Expansion
- Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects.
- Scope Expansion
- Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.)
3-Dimensional Expansion - Business Expansion & Portfolio Diversification
Source : JP Morgan Healthcare Conference 2021
Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance.
In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely,
John Rim President and CEO, Samsung Biologics
26 January 2021
Dear Investors,
This is John Rim, CEO of Samsung Biologics.
First, I want thank you all for your continued interest and support in Samsung Biologics.
Achieved "1 trillion won" in revenue within 9 yearslt would be an understatement to say that our daily lives have changed in 2020 due to hte COVID-19 pandemic. Yet even through the extraordinary global events of last year, Samsung Biologics, I ask for your continued warm attention and support. Sincerely,' sales volume increased for all three plants, and we achieved 1,164.8B KRW in revenue,
John Rim President and CEO, Samsung Biologics
an increase of 463B KRW(66%) from the previous year. And operating profit was reported at KRW292.8 billion, reflecting an operating margin of 25%, a 12%p increase of KRW201.1 billion, doubling our prior year's record attributable to substantial operating leverage. l ma very pleased to share that we kept our promise of "1 trillion won in 2020" as announced during our IPO in 2016.2020 Performance
- 47 CMO Accumulated Contracts
- Ground breaking for Plant 4 with capacity of 256,000L
- Geographical Expansion of CDO Lab
- Proprietary cell line launch 'S-CHOice'
From the onset of the global pandemic, Samsung Biologics maintained stable business operations for our valued clients, providing world-class development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic.
Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2,
John Rim President and CEO, Samsung Biologics
and near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services.2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely,
John Rim President and CEO, Samsung Biologics
As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years:
- Capacity Expansion
- By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion
- Geography Expansion
- Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects.
- Scope Expansion
- Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.)
3-Dimensional Expansion - Business Expansion & Portfolio Diversification
Source : JP Morgan Healthcare Conference 2021
Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance.
In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely,
John Rim President and CEO, Samsung Biologics